Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 4/6 |
Past Performance | 5/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Oncoclínicas do Brasil Serviços Médicos S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | R$7.25 |
52 Week High | R$13.00 |
52 Week Low | R$5.36 |
Beta | 1.01 |
11 Month Change | 17.31% |
3 Month Change | -1.49% |
1 Year Change | -37.82% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -62.06% |
Recent News & Updates
Earnings Tell The Story For Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3) As Its Stock Soars 27%
Jul 16Is Now An Opportune Moment To Examine Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3)?
Jul 03Investors Appear Satisfied With Oncoclínicas do Brasil Serviços Médicos S.A.'s (BVMF:ONCO3) Prospects As Shares Rocket 25%
Jun 01Recent updates
Earnings Tell The Story For Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3) As Its Stock Soars 27%
Jul 16Is Now An Opportune Moment To Examine Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3)?
Jul 03Investors Appear Satisfied With Oncoclínicas do Brasil Serviços Médicos S.A.'s (BVMF:ONCO3) Prospects As Shares Rocket 25%
Jun 01Oncoclínicas do Brasil Serviços Médicos S.A.'s (BVMF:ONCO3) Share Price Is Still Matching Investor Opinion Despite 27% Slump
Apr 17Oncoclínicas do Brasil Serviços Médicos' (BVMF:ONCO3) Earnings Are Weaker Than They Seem
Apr 03Oncoclínicas do Brasil Serviços Médicos (BVMF:ONCO3) Has A Somewhat Strained Balance Sheet
Mar 11What Does Oncoclínicas do Brasil Serviços Médicos S.A.'s (BVMF:ONCO3) Share Price Indicate?
Feb 17It's A Story Of Risk Vs Reward With Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3)
Dec 08Why Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3) Could Be Worth Watching
Nov 06Is Now The Time To Put Oncoclínicas do Brasil Serviços Médicos (BVMF:ONCO3) On Your Watchlist?
Sep 11Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3) Just Reported Earnings, And Analysts Cut Their Target Price
Apr 03Shareholder Returns
ONCO3 | BR Healthcare | BR Market | |
---|---|---|---|
7D | 1.4% | 1.1% | -0.4% |
1Y | -37.8% | -26.5% | -0.2% |
Return vs Industry: ONCO3 underperformed the BR Healthcare industry which returned -26.5% over the past year.
Return vs Market: ONCO3 underperformed the BR Market which returned -0.2% over the past year.
Price Volatility
ONCO3 volatility | |
---|---|
ONCO3 Average Weekly Movement | 14.5% |
Healthcare Industry Average Movement | 7.8% |
Market Average Movement | 4.6% |
10% most volatile stocks in BR Market | 8.8% |
10% least volatile stocks in BR Market | 2.5% |
Stable Share Price: ONCO3's share price has been volatile over the past 3 months.
Volatility Over Time: ONCO3's weekly volatility has increased from 9% to 15% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | n/a | Bruno Ferrari | www.grupooncoclinicas.com |
Oncoclínicas do Brasil Serviços Médicos S.A. provides medical services focused on clinical oncology and radiotherapy in Latin America. It offers services in the areas of chemotherapy, radiotherapy, hormone therapy, molecular target drugs, immunotherapy, bone marrow transplant, catheter heparinization, non-oncological infusions, laser therapy, myelogram - bone marrow biopsy, continuous care, and precision medicine. The company was founded in 2010 and is based in São Paulo, Brazil.
Oncoclínicas do Brasil Serviços Médicos S.A. Fundamentals Summary
ONCO3 fundamental statistics | |
---|---|
Market cap | R$3.69b |
Earnings (TTM) | R$211.03m |
Revenue (TTM) | R$5.65b |
17.5x
P/E Ratio0.7x
P/S RatioIs ONCO3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ONCO3 income statement (TTM) | |
---|---|
Revenue | R$5.65b |
Cost of Revenue | R$3.71b |
Gross Profit | R$1.94b |
Other Expenses | R$1.73b |
Earnings | R$211.03m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 13, 2024
Earnings per share (EPS) | 0.42 |
Gross Margin | 34.32% |
Net Profit Margin | 3.73% |
Debt/Equity Ratio | 163.5% |
How did ONCO3 perform over the long term?
See historical performance and comparison